Long-term effectiveness of therapy for common cause of kidney failure
Friday, July 20, 2018 - 10:31
in Health & Medicine
Among individuals with autosomal dominant polycystic kidney disease, those who were treated with tolvaptan for up to 11 years had a slower rate of kidney function decline compared with historical controls. Annualized kidney function decline rates of tolvaptan-treated patients did not change during follow-up.